The Underrated Ingredient That Could Help You Lose Weight, According to Dietitians
Dietitians say beans are the most underrated ingredient for weight loss.
Beans are packed with protein and fiber to keep you full and satisfied.
They also help with weight loss by supporting gut health and managing blood sugar.No one has to tell you that weight loss can feel challenging for so many reasons. Between the latest fad diets and social media messages insisting that special powder will melt off the pounds, it's hard to know what really works and what's just clever marketing.
While we wish there were a magic solution, dietitians agree that one of the best things you can do is to choose foods that have actually been shown to help with weight loss. Like beans. 'Beans are the unsung heroes of weight management,' says Drew Hemler, M.Sc., RD, CDN. 'They're inexpensive, versatile and loaded with a trio of fiber, protein and slow-digesting carbs that keep you full longer while curbing cravings.'
Read on to find out why beans are our MVP ingredient for weight loss, plus quick, tasty ways to add them to your favorite meals and snacks.
How Beans May Help with Weight Loss
They're Low in Calories, Yet Big on Volume
'Beans are relatively low in calories but high in volume, thanks to their fiber and water content,' says Hemler. 'That means you can eat a satisfying portion that fills you up without overloading on calories, which is an ideal combo for anyone trying to lose or manage weight.' For instance, 1 cup of canned black beans contains just 220 calories. At the same time, they're 75% water, which pumps up their volume.
Even though beans are low in calories, they pack a slew of vitamins and minerals, making them nutritional superstars. Lauren Harris-Pincus, M.S., RDN, points out that beans, like black, kidney, white, garbanzo and pinto beans, also provide potassium, a nutrient that we need for healthy blood pressure, yet most of us fall short of. So, in addition to helping with weight loss, they also fill in an important nutrition gap.
They're Packed with Protein and Fiber
Beans contain a dynamic weight-loss duo of protein and fiber. 'The protein, slowly digestible starches and soluble fiber in beans help slow gastric emptying and regulate blood sugar, and as a result, reduce hunger-driven cravings,' says Hemler. And when you feel full, you're a lot less likely to mindlessly munch, which may help you eat fewer calories. Their combo of protein and fiber is so powerful that one study found that people who ate roughly 1 cup of beans per day had a lower body mass index and body weight and smaller waist size compared to people who didn't usually eat beans.
While all beans differ slightly, 1 cup of canned black beans gives you a whopping 17 grams of fiber and 15 grams of protein.
They May Enhance Gut Health
A healthy gut microbiome doesn't just keep your digestive system running smoothly. It's also a key player in long-term weight management, helping manage appetite and blood sugar.
Regularly eating beans helps keep your gut bacteria in tip-top shape, which may translate to easier weight loss, says Harris-Pincus. That's because beans are rich in a hard-to-digest carbohydrate called resistant starch. After you eat, say, a bowl of bean chili, the resistant starch from the beans travels to your gut. When it gets there, your gut good bacteria gobble it up for food. As they do this, they produce helpful compounds, called short-chain fatty acids (SCFAs), linked to lower body weight, a reduced risk of obesity and lower blood sugar.
They May Promote Healthier Blood Sugar
Nearly one-third of U.S. adults are living with prediabetes. That doesn't just increase the risk of diabetes, it's also a sneaky cause of weight gain. Prediabetes often begins with a silent condition called insulin resistance, which can disrupt your ability to maintain a healthy weight. Trouble is, health care providers don't usually test for insulin resistance. So, many of us have it without even knowing it.
Eating beans might just help protect against insulin resistance and the weight gain that comes along with it. 'The plant-based protein and fiber in beans can aid in blood sugar control as well as increasing satiety to help people lose or maintain weight,' says Harris-Pincus. 'Beans also contain antioxidants, which clinical studies have shown may reduce insulin resistance, aiding weight management.' In addition to protein and fiber, beans contain antioxidant-rich substances called saponins, which have been shown to lower blood sugar and protect against insulin resistance.
Tips to Use Beans
Beans are incredibly versatile, working well in both sweet and savory dishes. And using canned beans can help you make mealtime magic happen in no time. To add more beans to your favorite dishes, try these dietitian-approved tips.
Blend them into dips: Swap in blended white beans for mayo or sour cream in creamy dips and spreads, like our five-star Loaded Black Bean Dip. It's a delicious way to add more protein and fiber to your day!
Use them to bulk up meals: Stir cannellini beans into a White Bean Soup with Pasta or some Tuscan White Bean Soup. Toss mixed beans into a steaming pot of Three-Bean Chili, or tuck black beans into tacos or Butternut Squash & Black Bean Enchiladas. You can even use beans to pump up the volume and protein in scrambled eggs and quiche!
Roast a bean-based snack: Roasted chickpeas are a wonderful canvas for sweet, salty and spicy snacks. If spicy is your thing, give these Spice-Roasted Chickpeas a try. Or, for a healthy way to satisfy your sweet tooth, roast a batch of Cinnamon-Sugar Roasted Chickpeas (toss them in your next yogurt parfait for a sweet and crunchy fiber punch!).
Puree them into sweet treats: Fold pureed chickpeas into a no-bake cookie dough or whip red lentils into a Chocolate-Banana Protein Smoothie.
Upgrade your toast: Mash your favorite beans with spices, a little lemon juice and olive oil to top your avocado toast. Or, for a new spin on ricotta toast, try our protein-packed Cannellini Bean & Herbed Ricotta Toast.
Our Expert Take
Nutrition experts unanimously agree that weight loss doesn't happen overnight. It's really about the small, sustainable changes that can add up over time. Like adding beans to your day. 'Including beans, lentils and chickpeas regularly in the diet is associated with numerous health benefits, including healthy weight maintenance, gut health and risk reduction for several chronic diseases,' says Harris-Pincus.
Beans are big in volume, yet low in calories and are loaded with filling fiber and protein. They may also support weight loss by keeping your gut bacteria happy and healthy and improving your body's ability to use insulin. 'Beans aren't just good for your waistline; they're great for your wallet, gut and the planet, too,' says Hemler. 'Whether you're going meatless or just adding more plants, beans bring big benefits in a small, humble package.' Plus, they're incredibly versatile. Whether you like them in dips, tacos, chili, soup, enchiladas or even smoothies or dessert, there are loads of good reasons to pop open a can!
Read the original article on EATINGWELL

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Fox News
11 minutes ago
- Fox News
Doctor reveals why he is 'concerned' about mental health screenings in Illinois schools
Dr. Leonard Sax, author of 'The Collapse of Parenting,' joins 'Fox & Friends' to discuss why he is concerned about a new law requiring schools in Illinois to screen kids' mental health.
Yahoo
39 minutes ago
- Yahoo
Mario and Courtney Lopez Team Up with NaturVet to Spotlight Award-Winning Pet Supplements at SuperZoo 2025
The duo will showcase NaturVet's offerings, led by All-In-One Daily Care, recently named "Dog Vitamin/Supplement Innovation of the Year" LAS VEGAS, Aug. 12, 2025 /PRNewswire/ -- Mario and Courtney Lopez are joining NaturVet at SuperZoo 2025 to celebrate the brand's refreshed look and inspire pet parents to take a proactive approach to their pets' health and wellness. The show is August 13-15 at Mandalay Bay Convention Center, and the beloved television personalities will appear at booth #9747 on day two for a media/VIP event. "Having Mario and Courtney Lopez join us at SuperZoo is incredibly exciting," said Geoff Granger, CEO at NaturVet. "We share a passion for helping pets live healthier, happier lives, and their involvement allows us to extend this message to even more pet parents." NaturVet's All-In-One Daily Care line was recently named "Dog Vitamin/Supplement Innovation of the Year" by the 2025 Pet Innovation Awards, a prestigious program that recognizes the most innovative companies, services and products in the global pet industry. With comprehensive, vet-formulated benefits and easy-to-give soft chews, the All-In-One line stood out for delivering real results for dogs at every life stage, from puppyhood through their senior years. NaturVet will showcase its award-winning All-In-One Daily Care line at SuperZoo, along with a range of new product innovations including: All-In-One Puppy Daily Care: A soft chew supplement with a hickory smoked bacon flavor designed to support the needs of growing puppies with six essential key benefits, including skeletal support, brain development, healthy digestion and immune health. Formulated for younger dogs, it features the exclusive dental care ingredient PlaqueOff® for added oral health support. All-In-One Adult Daily Care: A 10-in-1 soft chew supplement designed to support adult dogs with targeted benefits, including joint health, digestion, immunity, skin and coat health and more. Featuring a delicious hickory smoked bacon flavor and the exclusive dental care ingredient PlaqueOff®, it helps support overall health and well-being throughout adulthood. All-In-One Senior Daily Care: An 8-in-1 soft chew supplement designed to support aging dogs by targeting areas such as joint health, mobility and gut health, while also providing brain, heart and vision support. It features the exclusive ingredient PlaqueOff® for dental care and tailored ingredients that help support longevity and immunity. With its hickory smoked bacon flavor, the soft chews are easy to give to senior dogs. Lickable Supplements for Cats: A pump-dispensed supplement designed for easy dosing. Available in Hip & Joint, Calming and Multi-Vitamin formulas, it provides essential support in a mess-free format, making supplementation effortless for cat owners. Lickable Supplements for Dogs: A peanut butter-flavored supplement for dogs, available in Hip & Joint, Calming and Multi-Vitamin formulas. Designed for easy dosing with a pump, it offers a convenient, mess-free alternative to traditional supplements while addressing key dog health and wellness needs. SuperZoo attendees are invited to stop by booth #9747 to meet the NaturVet team, explore some of their best-selling products and see how the Lopez family is partnering with NaturVet to inspire happier, healthier pets. To learn more about NaturVet and its complete line of vet-formulated supplements, visit About NaturVet NaturVet is a 30-year pioneer and present-day innovator manufacturing high-quality pet products designed to support the health, wellness and quality of life for pets and pet parents. Headquartered in Southern California, NaturVet produces dog, cat and equine supplements including all-in-one vitamins and targeted solutions for calming, digestion, allergy aids, skin and joint support. Formulated by veterinarians and manufactured in-house to ensure quality, NaturVet's products are made with ingredients which are sourced from trusted global suppliers and tested to meet rigorous standards by the National Animal Supplement Council (NASC). For more information, visit View original content to download multimedia: SOURCE NaturVet Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates
Topline data from SERENITY At-Home Phase 3 trial for acute treatment of agitation associated with bipolar disorders or schizophrenia expected in August FDA meeting scheduled in August and is intended to support potential sNDA submission for label expansion of IGALMI® in the at-home setting Publication of non-clinical data in Frontiers in Pharmacology suggests potential applications of BXCL501 in chronic conditions BioXcel Therapeutics strengthens cash position NEW HAVEN, Conn., Aug. 12, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today reported its financial results for the second quarter of 2025 and announced that its SERENITY At-Home pivotal Phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia was complete. Topline results from the study are expected in August. "We are incredibly excited about the upcoming top-line data readout for our SERENITY At-Home Phase 3 trial – our primary market research and preliminary results regarding the frequency of agitation episodes during the trial suggest a target addressable market meaningfully larger than our original estimate of 23 million agitation episodes in the at-home setting annually,' said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. 'This expanded opportunity estimate presents a significant prospect to help many bipolar disorder and schizophrenia patients, fulfilling our core mission." BXCL501 Late-Stage Clinical Programs SERENITY Program SERENITY At-Home Phase 3 Trial: The SERENITY At-Home Phase 3 trial is a double-blind, placebo-controlled study designed to evaluate the safety of a 120 mcg dose of BXCL501 for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting: The trial enrolled more than 200 patients across 22 sites nationwide, with no single site enrolling more than 11% of the total patient population. The vast majority of patients dosed completed the full 12-week study. Data from more than 2,200 agitation episodes was collected. The distribution of enrolled patients was balanced between the two patient populations, bipolar disorders and schizophrenia. The trial received two favorable recommendations from the Data Safety Monitoring Board (DSMB). TRANQUILITY Program TRANQUILITY In-Care Phase 3 Trial: designed as a double-blind, placebo-controlled study to evaluate the efficacy and safety of a 60 mcg dose of BXCL501 for acute treatment of agitation associated with Alzheimer's dementia in the care setting. The program remains part of the Company's broader development strategy. The Company is evaluating CROs for trial initiation. BXCL501 in Chronic Conditions Research published in the journal Frontiers in Pharmacology showed that BXCL501 caused a significant reduction in behaviors induced by stress in translatable behavioral models related to psychiatric disorders, providing further support for the drug's mechanism of action and potential suitability for broadly addressing stress-related disorders in addition to agitation. Corporate Updates IGALMI® Market Presence The Company is continuing to supply IGALMI® to patients and providers in the institutional setting, and build brand awareness, with minimal commercial resources. Second Quarter 2025 Financial Results Net revenue from IGALMI® was $120 thousand for the second quarter of 2025, compared to $1.1 million for the same period in 2024. Cost of Goods Sold for the second quarter of 2025 was $107 thousand, compared to $62 thousand for the same period in 2024. Cost of goods sold is related to the costs to produce, package, and deliver IGALMI® to customers, as well as costs related to excess or obsolete inventory. There was $95 thousand for charges for reserves for excess or obsolete inventory in the three months ended June 30, 2025, compared to none for the same period in 2024. Research and Development (R&D) expenses were $10.3 million for the second quarter of 2025, compared to $8.0 million for the same period in 2024. The increase in expenses was primarily attributable to an increase in clinical trial activity associated with the SERENITY at-home Phase 3 studies and offset by a decrease in personnel related to the company's reprioritization. Selling, General and Administrative (SG&A) expenses were $5.6 million for the second quarter of 2025, compared to $9.5 million for the same period in 2024. The decreased expenses were attributable to a decrease in personnel and related costs, lower professional fees, and lower commercial and marketing costs resulting from reprioritization actions taken in 2024. Net Loss: BioXcel Therapeutics an operating loss of $15.9 million and a net loss of $19.2 million for the second quarter of 2025, compared to an operating loss of $17.3 million and net loss of $8.3 million for the same period in 2024**. The Company used $12.6 million in operating cash during the second quarter of 2025. Cash and cash equivalents and restricted cash totaled $18.6 million as of June 30, 2025. This does not include an additional $11.5 million of gross proceeds from sales pursuant to the company at-the-market program and $3.6 million received in connection with the exercise of outstanding warrants subsequent to quarter-end. **In the second quarter of 2024, the loss from operations of $17.3 million was offset by unrealized gains of $12 million related to derivative liabilities. About BXCL501Outside of its approved indication by the U.S. Food and Drug Administration as IGALMI® (dexmedetomidine) sublingual film, BXCL501 is an investigational proprietary, orally dissolving film formulation of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist. BXCL501 is under investigation by BioXcel Therapeutics for the acute treatment of agitation associated with Alzheimer's dementia and for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in the at-home setting. The safety and efficacy of BXCL501 for these investigational uses have not been established. BXCL501 has been granted Breakthrough Therapy designation by the FDA for the acute treatment of agitation associated with dementia and Fast Track designation for the acute treatment of agitation associated with schizophrenia, bipolar disorders, and dementia. About the SERENITY At-Home Phase 3 TrialThe SERENITY At-Home Phase 3 trial is a double-blind, placebo-controlled study designed to evaluate the safety of a 120 mcg dose of BXCL501 for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting. The trial is designed to evaluate 200 patients with a history of agitation episodes residing at home either alone or with caregivers/informants. Patients are self-administering 120 mcg of BXCL501 or placebo when agitation episodes occur over the 12-week trial period, with safety data (adverse events) collected during the trial. In addition, patients or caregivers/informants will complete a modified global impression of severity (mCGIs) and a clinical global impression of change (mCGI-C) two hours after dosing as an exploratory endpoint to evaluate use in the outpatient setting. About the TRANQUILITY In-Care Phase 3 Trial The TRANQUILITY In-Care trial is designed as a double-blind, placebo-controlled study to evaluate the efficacy and safety of a 60 mcg dose of BXCL501 over a 12-week period for agitation associated with Alzheimer's dementia in the care setting. The trial is expected to enroll approximately 150 patients 55 years and older who have mild, moderate, or severe dementia with mini-mental state examination scores of 0 to 25 and who reside in skilled nursing facilities, memory care units, or assisted living facilities. Patients will self-administer 60 mcg of BXCL501 or placebo when episodic agitation episodes occur over the trial period. The primary endpoint is expected to be a change from baseline in the Positive and Negative Syndrome Scale-Excitatory Component (PEC) total score at two hours post-first dose. Additional PEC and Clinical Global Impressions – Improvement Scale measurements will also be obtained during the trial. About IGALMI® (dexmedetomidine) sublingual film INDICATION IGALMI® (dexmedetomidine) sublingual film is a prescription medicine, administered under the supervision of a health care provider, that is placed under the tongue or behind the lower lip and is used for the acute treatment of agitation associated with schizophrenia and bipolar disorder I or II in adults. The safety and effectiveness of IGALMI has not been studied beyond 24 hours from the first dose. It is not known if IGALMI is safe and effective in children. IMPORTANT SAFETY INFORMATION IGALMI can cause serious side effects, including: Decreased blood pressure, low blood pressure upon standing, and slower than normal heart rate, which may be more likely in patients with low blood volume, diabetes, chronic high blood pressure, and older patients. IGALMI is taken under the supervision of a healthcare provider who will monitor vital signs (like blood pressure and heart rate) and alertness after IGALMI is administered to help prevent falling or fainting. Patients should be adequately hydrated and sit or lie down after taking IGALMI and instructed to tell their healthcare provider if they feel dizzy, lightheaded, or faint. Heart rhythm changes (QT interval prolongation). IGALMI should not be given to patients with an abnormal heart rhythm, a history of an irregular heartbeat, slow heart rate, low potassium, low magnesium, or taking other drugs that could affect heart rhythm. Taking IGALMI with a history of abnormal heart rhythm can increase the risk of torsades de pointes and sudden death. Patients should be instructed to tell their healthcare provider immediately if they feel faint or have heart palpitations. Sleepiness/drowsiness. Patients should not perform activities requiring mental alertness, such as driving or operating hazardous machinery, for at least 8 hours after taking IGALMI. Withdrawal reactions, tolerance, and decreased response/efficacy. IGALMI was not studied for longer than 24 hours after the first dose. Physical dependence, withdrawal symptoms (e.g., nausea, vomiting, agitation), and decreased response to IGALMI may occur if IGALMI is used longer than 24 hours. The most common side effects of IGALMI in clinical studies were sleepiness or drowsiness, a prickling or tingling sensation or numbness of the mouth, dizziness, dry mouth, low blood pressure, and low blood pressure upon standing. These are not all the possible side effects of IGALMI. Patients should speak with their healthcare provider for medical advice about side effects. Patients should tell their healthcare provider about their medical history, including if they suffer from any known heart problems, low potassium, low magnesium, low blood pressure, low heart rate, diabetes, high blood pressure, history of fainting, or liver impairment. They should also tell their healthcare provider if they are pregnant or breastfeeding or take any medicines, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Patients should especially tell their healthcare provider if they take any drugs that lower blood pressure, change heart rate, or take anesthetics, sedatives, hypnotics, and opioids. Everyone is encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You can also contact BioXcel Therapeutics, Inc. at 1-833-201-1088 or medinfo@ Please see full prescribing information at About BioXcel Therapeutics, Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. For more information, please visit Forward-Looking StatementsThis press release includes 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements related to: the Company's planned advancement of its TRANQUILITY and SERENITY trials and the trial designs thereof; potential market opportunity for BXCL501; release of topline data from the ongoing SERENITY trial; the submission of an sNDA to the FDA; the supply of IGALMI through existing distribution channels; the potential for the results from the Company's completed, ongoing and proposed clinical trials to support regulatory approvals for its product candidates. When used herein, words including 'anticipate,' 'believe,' 'can,' 'continue,' 'could,' 'designed,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company's current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; the impact of the reprioritization; its significant indebtedness, ability to comply with covenant obligations and potential payment obligations related to such indebtedness and other contractual obligations; the Company has identified conditions and events that raise substantial doubt about its ability to continue as a going concern; its limited experience in drug discovery and drug development; risks related to the TRANQUILITY program; its dependence on the success and commercialization of IGALMI®, BXCL501, BXCL502, BXCL701 and BXCL702 and other product candidates; the number of episodes of agitation and the size of the Company's total addressable market may be overestimated, and approval that the Company may obtain may be based on a narrower definition of the patient population; its lack of experience in marketing and selling drug products; the risk that IGALMI or the Company's product candidates may not be accepted by physicians or the medical community in general; the Company still faces extensive and ongoing regulatory requirements and obligations for IGALMI; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; undesirable side effects caused by the Company's product candidates; its novel approach to the discovery and development of product candidates based on EvolverAI; the significant influence of and dependence on BioXcel LLC; its exposure to patent infringement lawsuits; its reliance on third parties; its ability to comply with the extensive regulations applicable to it; impacts from data breaches or cyber-attacks, if any; risks associated with the increased scrutiny relating to environmental, social and governance (ESG) matters; risks associated with federal, state or foreign health care 'fraud and abuse' laws; and its ability to commercialize its product candidates, as well as the important factors discussed under the caption 'Risk Factors' in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC's website at and the Investors section of the Company's website at These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release. Contact Information Corporate/InvestorsRusso PartnersNic 1.303.482.6405 MediaRusso PartnersDavid 1.858.717.2310 Source: BioXcel Therapeutics, is a registered trademark of BioXcel Therapeutics, Inc. BioXcel Therapeutics, Inc. Statements of Operations (Unaudited, in thousands, except per share amounts) Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 Revenues Product revenues $ 120 $ 1,104 $ 288 $ 1,686 Operating expenses Cost of goods sold 107 62 121 141 Research and development 10,256 8,032 14,810 19,433 Selling, general and administrative 5,609 9,450 11,308 22,715 Restructuring costs - 856 - 856 Total operating expenses 15,972 18,400 26,239 43,145 Loss from operations (15,852 ) (17,296 ) (25,951 ) (41,459 ) Other (income) expense Interest expense, net 4,222 3,700 8,215 7,307 Interest income (230 ) (671 ) (509 ) (1,618 ) Other (income) expense, net (657 ) (12,026 ) (7,216 ) (12,058 ) Net loss and comprehensive loss $ (19,187 ) $ (8,299 ) $ (26,441 ) $ (35,090 ) Net loss per share - basic and diluted $ (2.45 ) $ (3.30 ) $ (4.17 ) $ (15.78 ) Weighted average shares outstanding - basic and diluted 7,843 2,516 6,347 2,223 Condensed Balance Sheets (Unaudited, in thousands) June 30, December 31, 2025 2024 Cash and cash equivalents and restricted cash $ 18,575 $ 29,854 Total assets $ 25,789 $ 38,338 Total liabilities $ 133,456 $ 131,439 Total stockholders' equity (deficit) $ (107,667 ) $ (93,101 ) Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data